AKTX
Akari TherapeuticsAKTX
AKTX
$3.32
2.21%
Market Cap: $39.7M
About: Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Employees: 12
0
Funds holding %
of 6,686 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more capital invested
Capital invested by funds: $326K [Q1] → $488K (+$162K) [Q2]
25% more funds holding
Funds holding: 8 [Q1] → 10 (+2) [Q2]
0% less ownership
Funds ownership: 0% [Q1] → 0% (-0%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for AKTX.